Webinar: Why Patient-Specific Insulin Dosing Matters. Watch for free today!
: Support you can count on.When you choose EndoTool from Monarch Medical Technologies, you receive a true partner in inpatient glucose management. EndoTool’s comprehensive support measures ensure your team is always equipped to deliver the best patient care.
24/7 assistance
Our support team is available 24/7/365 to provide the technical and clinical guidance your team needs to navigate EndoTool’s dosing recommendations with confidence. This continuous support is available to all EndoTool customers at no additional cost for the lifetime of your contract.
Dedicated support
As an EndoTool customer, you’ll have the ongoing support of your own dedicated clinician and customer success manager. They will be your consistent point of contact, helping you achieve patient safety targets, improve workflows, and optimize your use of EndoTool.
Ongoing education
Effective staff education is crucial for improving compliance with insulin management protocols. Our training strategy focuses on building and continually advancing your clinical team's knowledge of EndoTool operation. We offer onsite, hands-on training as well as remote training and eLearning modules compatible with your LMS system.
Customer success story
Sandy Fogel, MD, FACS | Carilion Clinic
Support by professionals in the field
Nurses
Providers
Diabetes educators
IT specialists
Clinical leadership
Quality assurance
Real world results
Webinars
Why Every Health System Should Use Patient-Specific Insulin Dosing Software
Join healthcare leaders from Atrium Health, CaroMont Regional Medical Center, Temple University Hospital, and Trinity Health for an in-depth panel discussion on the benefits of patient-specific insulin dosing technology.
eBooks and How-to Guides
How to Select the Right Insulin Dosing Solution
This toolkit helps hospital teams evaluate options, spot critical gaps, and choose with confidence.
Case Study
Corewell Health Slashes DKA Costs by Nearly $1M in 18 Months
A retrospective review evaluated DKA patients treated between January 2023 – June 2024. Outcomes were compared against Vizient’s risk-adjusted expected values and a national benchmark group of 115 academic medical centers.
"*" indicates required fields
